Search Symbol

Most Active Stocks

NIACL

HDFCBANK

DMART

VBL

TATAMOTORS

ICICIBANK

JAYNECOIND

RELIANCE

BHARTIARTL

EBGNG

AXISBANK

TCS

INFY

WAAREEENER

AMBER

KOTAKBANK

M&M

SBIN

INDIGO

Glenmark Pharmaceuticals Limited

Drug Manufacturers - Specialty & Generic | Healthcare

Company Overview

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Key Information

Market Cap

608961495040

Current Price

2157.9

52 Week Range

1275.5 - 2284.8

Previous Close

2184.8

Open

2190.1

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Contact Details

Address

Glenmark House, B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East), Mumbai, 400099, India

Phone

+91-22401-89999

Fax

+91-22401-89986

Website

https://www.glenmarkpharma.com

Financials

Day Low

2149.2

Day High

2200.9

Dividend Yield

0.11

PE Ratio

58.101776

Earnings Per Share

37.14

Beta

0.264

EBITDA

24651030528

Book Value

304.497

EPS

76.61592

Company Officers

Name	Title	Age	Year Born
Mr. Glenn Mario Saldanha	Chairman, MD & CEO	54	1970
Ms. Cherylann Maria Pinto B.Pharm	Executive Director of Corporate Services & Executive Director	57	1967
Mr. Harish Vinayak Kuber	Company Secretary & Compliance Officer	-	-
Mr. Alind Sharma	President and Chief Human Resources Officer	53	1971
Mr. Ulhas R. Dhuppad	President & Head of Global Pharmaceutical Development	57	1967
Mr. Indrajit Bose	President & Chief Quality Officer	-	-
Mr. Brijlal Motwani	President & Global Head of Formulation Operations	-	-
Mr. Alok Malik	President & Business Head of India Formulations	-	-
Mr. Christoph Stoller	President and Business Head of Europe & Emerging Markets	-	-
Mr. Marc T. Kikuchi B.A., M.B.A.	President & Business Head of North America	55	1969